Matthias Pinter

Hepatologist @ Medical University of Vienna with a special interest in liver cancer

[Debbie Shawcross @DebbieShawcros1]

The @easlnews team have been in sunny Geneva making the final preparations for the #EASLCongress2026 🇪🇸and celebrating EASL’s 60th Birthday! 🎂
Have you registered? There is still time 27-30th May 2026

[EASLnews @EASLnews]

✨The full scientific programme for #EASLCongress 2026 is now live!

From late breaking science and state of the art lectures to interactive workshops, skills learning and multidisciplinary discussions, the programme captures the full scope and momentum of modern hepatology.

With more than 8,000 delegates set to gather in Barcelona on 26-30 May, now is the time to explore the sessions, discover speakers and start shaping your personal Congress experience.

Explore the full programme and start planning today!
🔗 https://t.co/QjbOH6vjIG

@DebbieShawcros1 @analleo

[EASLnews @EASLnews]

⭐️As the EASL #LiverCancerSummit comes to an end, a sincere thank you to all organisers, faculty, industry partners, and our 598 participants for three outstanding days of science, collaboration and shared commitment to improving outcomes for people with liver cancer, that unfolded in Edinburgh.

An inspiring meeting, and a strong platform for what comes next! We look forward to seeing you again in Valencia on 14-16 January 2027!

👉Registered delegates can access content from the Summit on demand: https://t.co/QWE4DA2fqh

@josepmllovet @IreneBargellini @DJPinato @PinterMatthias @EASLedu

[EASLnews @EASLnews]

📄Share your new findings and connect with the liver community by submitting an abstract to the #EASLCongress 2026, taking place on 27-30 May in Barcelona!

With more than 2,000 submissions last year, it is a great place to showcase your work.

Take this chance to join an international event, add your ideas to the discussion and be considered for awards.

👉Send your abstract by 6 January 2026! https://t.co/6NxBwlZ6Lx

@DebbieShawcros1 @analleo @aelsharkawy75 @RuiCastroHD @bogdanprocopet @fprusso73 @SaSi_Lens @PinterMatthias

[EASLnews @EASLnews]

🚨 Last chance for early registration!

Be part of the EASL #LiverCancerSummit 2026, a leading event dedicated to advancing the science and care of liver cancer.

Join world-renowned experts, researchers, and clinicians to explore the latest breakthroughs, evolving standards of care, and key controversies in HCC and related malignancies.

🗓 Early fee deadline: TOMORROW, 28 October
🔗 Don’t miss out – register today and secure your spot at a reduced rate! https://t.co/JbRMg3KqUL

💙 EASL Members enjoy even greater discounts – become a member and benefit now.

@DebbieShawcros1 @analleo @IreneBargellini @josepmllovet @DJPinato @PinterMatthias

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab https://t.co/fYZt67kLCN
@A_DAlessioMD @xander_petrenko @PinterMatthias @DJPinato

[EASLnews @EASLnews]

🚨 Last call for abstracts!

Tomorrow, 21 October, is the final deadline to submit your work for the EASL #LiverCancerSummit 2026. Don’t miss the chance to share your latest research, connect with global experts, and shape the future of liver cancer care.

The Summit will bring together the international liver oncology community to explore the latest advances in research, clinical practice, and innovation.

Join us and be part of the conversation driving progress in liver oncology!
👉https://t.co/Ao6pyStoPt

@DebbieShawcros1 @analleo @josepmllovet @PinterMatthias @DJPinato @IreneBargellini

[EASLnews @EASLnews]

HCC neuroendocrine transition refers to the rare process where HCC develops features of neuroendocrine tumors, leading to more aggressive disease and challenging treatment decisions.

Register now to join the upcoming EASL Molecular Tumour Board to explore what this means for clinical management and research: https://t.co/8TbwJedDPm

Faculty @VChernyakMD, @ma5RN, @MarcoSanduzzi, @siadaniela and @Vaital73 are looking forward to discussing these cases!

#LiverTwitter #LiverX

[EASLnews @EASLnews]

🌟 We are thrilled to announce that registration and abstract submission are now officially open for #EASLCongress 2026!

📍 Taking place in Barcelona, Spain, from 27–30 May 2026, this is the must-attend event for all who are passionate about advancing hepatology. Whether you are a clinician, researcher, policymaker, or trainee, EASL Congress offers something for everyone.

🔬 What makes EASL Congress 2026 unmissable?
- A scientific programme covering every track in hepatology: clinical practice, basic science, translational research, and public health.
- Diverse formats that allow you to engage with the content most relevant to your expertise.

📢 Abstract submission is open until 6 January 2026 https://t.co/6NxBwlZ6Lx
💡 Early bird registration is open until 13 January 2026 https://t.co/7kROJ9gjCa
🔗https://t.co/iz0EO5boBt

#LiverTwitter #LiverX

[EASLnews @EASLnews]

⏳ Less than one month left to submit your abstract!
Be part of the EASL #LiverCancerSummit 2026, the leading global meeting on liver tumours.

The programme will cover:
🔬 Basic, translational and clinical research
🌍 Cutting-edge insights from international experts
💡 Discussions shaping the future of liver cancer care

📢 Abstract deadline: 21 October 2025
https://t.co/Ao6pyStoPt
Don’t miss your chance to present your research and connect with the global liver cancer community.
💡 Register early: 28 October
https://t.co/JbRMg3KqUL

#LiverTwitter #LiverX

[EASLnews @EASLnews]

Save the date for the upcoming EASL Molecular Tumour Board, taking place Wednesday 15 October at 18:00 CEST!

Experts @VChernyakMD, @ma5RN, @MarcoSanduzzi, @siadaniela and @Vaital73 will discuss a case of HCC-neuroendocrine transition.

Register now: https://t.co/8TbwJedDPm

#LiverTwitter #LiverX

[EASLnews @EASLnews]

🎗️Join us at the EASL #LiverCancerSummit 2026
📅 22–24 January 📍 Edinburgh, UK

Each day promises new highlights in the field of liver tumours. Browse the full programme to create an agenda tailored to your interests!
👉https://t.co/5y4Pyd41TM

Day 1: #MASLD and #HCC links, novel surveillance and biomarkers, AI, and emerging molecular therapies.
Day 2: Advances in surgery, transplant, locoregional therapies, pivotal trials, and debates in liver cancer care.
Day 3: Systemic therapies, treatment sequencing, immunotherapy, and the future of biomarker-driven, equitable, patient-centred care.

👉 Submit your abstract by 21 October https://t.co/Ao6pyStoPt
👉 Register with early fees by 28 October https://t.co/JbRMg3KqUL

@DebbieShawcros1 @analleo @DJPinato @IreneBargellini @DJPinato @PinterMatthias

[EASLnews @EASLnews]

🎗️Register and submit your abstract to the EASL Liver Cancer Summit 2026, 22-24 January, Edinburgh, UK.

The leading global event for liver cancer research and clinical practice is back.

🔬 Rapid advances in #HCC and #CCA are transforming treatment strategies, from immunotherapy and novel systemic therapies to AI-driven diagnostics.

✨ Why attend?
✔️ Learn the latest on primary liver cancer science and care
✔️ Connect with global experts in a dynamic, collaborative setting
✔️ Gain fresh insights into trials, guidelines, and personalised treatment
Join the global liver cancer community and shape the future of patient care.

👉21 October: Abstract submission
👉28 October: Early Fee Registration

https://t.co/JqjtUttfU7

@IreneBargellini @DJPinato @PinterMatthias @EASLedu @DebbieShawcros1 @analleo

[EASLnews @EASLnews]

EASL is deeply saddened to share the news of the passing of Professor Michael P. Manns (1951–2025).

A visionary leader in hepatology, Professor Manns shaped the field through his pioneering research in viral hepatitis, autoimmune liver diseases, transplantation and regenerative medicine. He served as Director of the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School for nearly three decades, and held leading roles in Hep-Net, the German Liver Foundation, UEG, and EASL.

His scientific excellence, dedication and mentorship inspired colleagues around the world. Professor Manns received numerous awards, including the EASL Recognition Award (2007) and the UEG Lifetime Achievement Award (2022).

EASL extends heartfelt condolences to his family, friends and colleagues. His legacy will continue to inspire generations of hepatologists.

[EASLnews @EASLnews]

🌟 Registration and abstract submission now open for the EASL Liver Cancer Summit 2026! 🌟

🗓️ 22–24 January 2026
📍 Edinburgh, UK

Join the global liver cancer community for three transformative days of science, innovation, and collaboration. The EASL Liver Cancer Summit is the meeting for everyone involved in the care, research, and advocacy of liver cancer.

Key Deadlines:

📌 Abstract submission: 11 August – 21 October 2025
📌 Early registration: 11 August – 28 October 2025

👉Secure your spot & send in your research: https://t.co/JqjtUttfU7

@DebbieShawcros1 @analleo @DJPinato @BargelliniIrene @PinterMatthias

[Matthias Pinter @PinterMatthias]

@NaultJc Vienna 2025 😉

[EASLnews @EASLnews]

🆕We are excited to announce the launch of the new Fellowship Programme!
Are you looking to grow your skills and connect with peers across Europe? Do you want to advance your research in liver disease?
Discover our two fellowship types and apply by 1 September 2025!

🔗 https://t.co/dWRGj6ij2d

#LiverTwitter #LiverX

[EASLnews @EASLnews]

Last chance to apply for the EASL-@AASLDtweets Masterclass!
This is a key opportunity to sharpen your leadership, communication & career skills! From mentorship to publishing, negotiation to networking — prepare to thrive in academic & clinical life.

❗Application deadline: this Sunday, 13 July 23:59 CEST

Discover the programme and apply on https://t.co/lS18QD91CB

#LiverX #LiverTwitter

[Gut Journal @Gut_BMJ]

#GUTImages from the #RecentAdvancesInClinicalPractice paper by Pinter (@PinterMatthias) et al on

"Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction" via

https://t.co/Df0rvDghcm

@DJPinato #HCC

[EASLnews @EASLnews]

Are you interested in building the future of hepatology with us? Do you have a strong scientific track record in Immune-mediated and Cholestatic Diseases?

The EASL Scientific Committee is looking for one new member!

Read more and apply by 15 June 23:59 CEST on: https://t.co/ZIZE4QRo07

#LiverTwitter #LiverX